A novel model-based approach for dose determination of glycopyrronium bromide in COPD

BACKGROUND: Glycopyrronium bromide (NVA237) is an inhaled long-acting muscarinic antagonist in development for treatment of COPD. This study compared the efficacy and safety of once-daily (OD) and twice-daily (BID) glycopyrronium bromide regimens, using a novel model-based approach, in patients with...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Arievich, Helen, Overend, Tim, Renard, Didier, Gibbs, Michael, Alagappan, Vijay, Looby, Michael, Banerji, Donald
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2012
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3528484/
https://ncbi.nlm.nih.gov/pubmed/23217058
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2466-12-74
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky